CULLINAN THERAPEUTICS INC (CGEM)
Health Care · Clinical-stage biopharmaceuticals · NASDAQ
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing targeted, innovative therapies for cancer and autoimmune diseases.
What CULLINAN THERAPEUTICS INC does
Cullinan Therapeutics is a biopharmaceutical company focused on discovering and developing therapeutic candidates across multiple disease areas. The company is in the preclinical and clinical development stages with a portfolio of product candidates, including a collaboration with Taiho Pharmaceutical Co., Ltd. The company does not yet have approved products on the market and generates no meaningful revenue from product sales.
Themes: Clinical-stage therapeutics, Drug discovery and development, Biopharmaceutical R&D, Strategic collaborations
Fundamentals
- Price$21.68 as of 2026-08-21 close
- Market cap$1.4B as of 2026-08-21
- 1-year return+182.7% 2025-08-21 close $7.67 → 2026-08-21 close $21.68
- P/En/a negative earnings
- Net margin-346.2% as of 2026-08-24
- ROE-52.9% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta-0.06 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How CGEM compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CULLINAN THERAPEUTICS INC looks technically
CULLINAN THERAPEUTICS INC (CGEM) is trading 56.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 178 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 69, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 10 trading days ago (its momentum flipped positive). It made a new 20-day high about 3 trading days ago. It is 3.8% below its 52-week high (its highest price of the past year).
Trend
8
| Distance from the 200-day | it is trading 56.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +56.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $17.76 | $17.76 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $13.82 | $13.82 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 35 calendar days ago — the swings before that are what the structure reading is measured on | 35 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 16. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 178 trading days ago — a "golden cross", a bullish long-term signal | 178 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with buyers in control | 26.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 69, neither overbought (above 70) nor oversold (below 30) | 68.6 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($16.38 to $22.54) — its "stochastic" reading is 86 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 86.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 10 trading days ago (its momentum flipped positive) | 10 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $22.54 | $22.54 |
|---|---|---|
| From the 52-week high | it is 3.8% below its 52-week high (its highest price of the past year) | -3.8% |
| Above the 52-week low | it is 281.7% above its 52-week low (its lowest price of the past year) | +281.7% |
| Below the 52-week high | it is 3.8% below its highest point of the past year | 3.8% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $59.85 (set on 2021-03-10) | $59.85 |
| Given back of the 52-week move | over the past year its closes ranged ($5.75 to $22.52), and it has given back only a small part of its rise from last year’s low — 5% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $11.62 to $12.16. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 5.0% |
| From the all-time high | it is 63.8% below its all-time high | -63.8% |
| Nearest price level | it is trading 13.8% above a support level at $18.70 — a price it turned at twice since 2024-09-20, most recently on 2026-07-09. Since 2024-08-21 it has 13 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -13.8% |
| All-time low | its lowest closing price on record is $5.68 (set on 2025-10-03) | $5.68 |
| Above the all-time low | it is 281.7% above its all-time low | +281.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 82% of the past ~6 months) | 82nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.17 between its high and its low — about 5.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.17 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $15.28 and $22.50 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $15.28 – $18.89 – $22.50 |
| Typical daily range (% of price) | its price moves about 5.4% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.4% |
| Stretch from the 200-day average | it is trading 6.7 daily ranges above its 200-day average price (56.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.7 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.20× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 2.0% since the prior reading | +2.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.01 toward sell |
Candlestick patterns
2
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bullish engulfing | 9 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 9 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.6% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.6% |
|---|---|---|
| Open gap | it gapped 3.6% above the previous close 2 sessions ago and has not traded back through the level it left behind at 20.84 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.5% |
| Gap filled | a 2.4% gap down opened on 2026-08-14 has been "filled" 5 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 5 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 17.7 percentage points (the stock gained 20.0% while the market gained 2.3%) | +17.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 52.0 percentage points (the stock gained 55.1% while the market gained 3.1%) | +52.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 47.8 percentage points (the stock gained 58.8% while the market gained 11.1%) | +47.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 162.2 percentage points (the stock gained 182.7% while the market gained 20.5%) | +162.2% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 30% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.3% of the share price. | +30.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 44% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $15.05 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +44.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 8% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $20.12 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +7.8% |
Price levels it has turned at before
CGEM last closed at $21.68 on 2026-08-21. Since 2024-08-21 it has turned at 13 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $18.70 | Support | 13.8% below the last close | turned there twice · 2024-09-20 to 2026-07-09 |
| $16.67 | Support | 23.1% below the last close | turned there three times · 2026-02-27 to 2026-05-29 |
| $15.89 | Support | 26.7% below the last close | turned there five times · 2024-09-23 to 2026-08-03 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $16.00.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · beating the market · Printed a doji candle | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.09 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$32.36 range $23.00 – $42.00; median $30.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CGEM
- Consensus EPS estimate-$0.8477 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical trial success is uncertain; the company's product candidates may fail to demonstrate efficacy or safety, delaying or preventing regulatory approval and commercialization","Regulatory approval is not guaranteed; the company depends on obtaining and maintaining regulatory clearances for investigational new drug applications and new drug applications on unpredictable timelines","The company is unprofitable with significant ongoing losses and cash burn, requiring additional financing to continue operations and fund clinical development programs"]
What changed in the latest 10-Q
AI-assisted comparison of CGEM's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Reworded:
- Reference to Annual Report changed from 'for the year ended December 31, 2024 (the "2024 10-K"), filed with the Securities and Exchange Commission (the "SEC") on February 27, 2025' in older filing to 'for the year ended December 31, 2025 (the "2025 10-K"), filed with the Securities and Exchange Commission (the "SEC") on March 10, 2026' in newer filing
- Notes:
- Comparison limited to boilerplate introductory language; text appears truncated at 'Please also refer to those factors described in "Part I,' in both filings
Risk Factors
- Reworded:
- Reference updated from '2024 10-K' to '2025 10-K' (annual report year-end reference changed from December 31, 2024 to December 31, 2025) in the 2026-05-07 filing
- Regulatory filings language changed from 'investigational new drug applications' to 'new drug applications or investigational new drug applications' in the 2026-05-07 filing
- Government shutdown reference changed from 'the U.S. government shutdown' (specific past event) in 2025-11-06 filing to 'any potential future United States government shutdown' (prospective language) in 2026-05-07 filing
- Table of contents page numbers changed: Risk Factors moved from page 22 to page 19; subsequent items shifted accordingly in the 2026-05-07 filing
- Cross-reference in final paragraph updated from '2024 10-K' to '2025 10-K' in the 2026-05-07 filing
- Notes:
- Text comparison limited to the forward-looking statements and table of contents sections provided; the actual Item 1A Risk Factors content itself was not fully included in either source and therefore could not be assessed for changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 90 days0 buys · 1 sell ($142560) — 1 selling insider
- Last 180 days0 buys · 4 sells ($384996) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-06. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CGEM's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding CGEM as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 7,617,802
- Reported value $108,248,973
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
CGEM had 10,254,541 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
CGEM had 15.9% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 19.17 days to cover at the same settlement.
- Reported short interest (shares) 10,254,541
- Short interest (% of shares outstanding) 15.9%
- Prior settlement (shares) 10,285,963
- Reported change -0.31%
- Days to cover (reported) 19.17
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Amgen (AMGN)
- Bristol Myers Squibb (BMY)
- Merck & Co. (MRK)
- Roche (RHHBY)
- AstraZeneca (AZN)
- Novartis (NVS)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CGEM vs…
CULLINAN THERAPEUTICS INC is found in…
Frequently asked questions
What does CULLINAN THERAPEUTICS INC (CGEM) do?
Cullinan Therapeutics is a biopharmaceutical company focused on discovering and developing therapeutic candidates across multiple disease areas. The company is in the preclinical and clinical development stages with a portfolio of product candidates, including a collaboration with Taiho Pharmaceutical Co., Ltd. The company does not yet have approved products on the market and generates no meaningful revenue from product sales.
What sector is CULLINAN THERAPEUTICS INC (CGEM) in?
CULLINAN THERAPEUTICS INC (CGEM) is classified in the Health Care sector. Its industry is Clinical-stage biopharmaceuticals. It trades on NASDAQ.
Who are CULLINAN THERAPEUTICS INC's (CGEM) competitors?
Notable peers of CULLINAN THERAPEUTICS INC (CGEM) include Amgen, Bristol Myers Squibb, Merck & Co., Roche and AstraZeneca. This peer set is informational only — not financial advice.
Is CULLINAN THERAPEUTICS INC (CGEM) overbought or oversold right now?
CULLINAN THERAPEUTICS INC (CGEM) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 69, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CGEM come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.